Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 21/5/2019
SIETES contiene 92751 citas

 
 
 1 a 20 de 1772 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Booth CM, Detsky AS. From the $80 hamburger to managing conflicts of interest with the pharmaceutical industry. BMJ 2019;365:3 de mayo. [Ref.ID 103106]
2.Enlace a cita originalTiene citas relacionadas Cita con resumen
Agarwal A, Ioannidis JPA. PREDIMED trial of Mediterranean diet: retracted, republished, still trusted?. BMJ 2019;364:7 de febrero. [Ref.ID 103032]
3.Enlace a cita original Cita con resumen
Fuentes Camps I, Rodríguez A, Agustí A. Non-commercial vs. commercial clinical trials: a retrospective study of the applications submitted to a research ethics committee . Br J Clin Pharmacol 2018;84:junio. [Ref.ID 102808]
4.Enlace a cita original Cita con resumen
Ioannidis JPA. The proposal to lower P value thresholds to .005. JAMA 2018;319:1429-30. [Ref.ID 102667]
5.Enlace a cita original Cita con resumen
Gellad WF, Thorpe CT, Steiner JF, Voils CI. The myths of medication adherence. Pharmacoepidemiol Drug Saf 2017;27:diciembre. [Ref.ID 102186]
6. Cita con resumen
7.Enlace a cita original Cita con resumen
Bally M, Dendukuri N, Rich B, Nadeau L, Helin-Salmivaara A, Garbe E, Brophy JM. Risk of acute myocardial infarction with NSAIDs in real world use: bayesian meta-analysis of individual patient data. BMJ 2017;357:j1909. [Ref.ID 101568]
10. Cita con resumen
Hwang TJ, Carpenter D, Lauffenburger JC, Wang B, Franklin JM, Kesselheim AS. Failure of investigational drugs in late-stage clinical development and publication of trial results. JAMA Intern Med 2016;176:1826-33. [Ref.ID 100788]
11.Enlace a cita original
Garner P, Hopewell S, Chandler J, MacLehose H, Akl EA, Beyene J, Chang S, Churchill R, Dearness K, Guyatt G, Lefebvre C, Liles B, Marshall R, Martínez García L, Mavergames C, Nasser M, Qaseem A, Sampson M, Soares-Weiser K, Takwoingi Y, Thabane L, Trivella M, Tugwell P, Welsh E, Wilson EC, Schünemann HJ. When and how to update systematic reviews: consensus and checklist. BMJ 2016;354:i3507. [Ref.ID 100641]
12. Cita con resumen
Anónimo. Administration to remove roadblock to marijuana research. DIA Daily 2016:1. [Ref.ID 100571]
13. Cita con resumen
Solans-Domènech M, Permanyer-Miralda G. Evaluación del impacto de la investigación biomédica: ¿para quién?. Med Clin (Barc) 2016;146:491-3. [Ref.ID 100373]
14. Cita con resumen
Townsley DM, Dumitriu B, Biancotto A, Weinstein B, Chen C, Hardy N, Mihalek AD, Lingala S, Kim YJ, Yao J, Jones E, Gochuico BR, Heller T, Wu CO, Calado RT, Scheinberg P, Young NS. Danazol treatment for telomere diseases. N Engl J Med 2016;374:1922-31. [Ref.ID 100340]
15. Cita con resumen
Chen R, Desai NR, Ross JS, Zhang W, Chau KH, Wayda B, Murugiah K, Lu DY, Mittal A, Krumholz HM, Hines HH. Publication and reporting of clinical trial results: cross sectional analysis across academic medical centers. BMJ 2016;352:i637. [Ref.ID 100065]
16. Cita con resumen
Casassus B. France releases interim report on drug trial disaster. Lancet 2016;387:634-5. [Ref.ID 100049]
18. Cita con resumen
Naci H, Carter AW, Mossialos E. Why the drug development pipeline is not delivering better medicines. BMJ 2015;351:h5542. [Ref.ID 99639]
19. Cita con resumen
McCarthy M. Industry paid $6.5bn to US physicians and hospitals in 2014. BMJ 2015;351:h3697. [Ref.ID 99244]
20.Enlace a cita originalTiene citas relacionadas
Smith EMD, Foster HE, Beresford MW. The development and assessment of biological treatments for children. Br J Clin Pharmacol 2015;79:379-94. [Ref.ID 98956]
Seleccionar todas
 
 1 a 20 de 1772 siguiente >>